CRISPR Therapeutics AG has outlined its strategic priorities and key planned activities for 2026. The company aims to accelerate the global commercialization and adoption of CASGEVY®, with continued regulatory submissions, including for patients aged 5 to 11. Updates from clinical trials of investigational therapies such as CTX310™ for cardiovascular disease, CTX611™ targeting Factor XI, and zugocabtagene geleucel (zugo-cel) for autoimmune and oncology indications are expected in the second half of the year. A clinical trial for CTX460 in alpha-1 antitrypsin deficiency is planned to begin in mid-2026. Additionally, the company is advancing its regenerative medicine portfolio, moving its next-generation diabetes candidate, CTX213™, toward clinical development. CRISPR Therapeutics reports a strong balance sheet to support these initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623850) on January 12, 2026, and is solely responsible for the information contained therein.